Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Multiple Myeloma

Pfizer’s Elrexfio Posts Phase 3 PFS Win Over Standard Multiple Myeloma Regimen

The trial now tracks overall survival to inform future regulatory and treatment decisions.

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit